Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated (VRTX)
Compare

Vertex Pharmaceuticals Incorporated (VRTX) Shares Outstanding: 0.26

popular:market cap|pe ratio|revenue|price history|total return

Is Vertex Pharmaceuticals Incorporated’s shares outstanding high or low?

Vertex Pharmaceuticals Incorporated's shares outstanding of 0.26 is in line with its 5-year average of 0.26, near the low end of its 5-year range (0.26–0.26).

The shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX) is 0.26. It is below its 12-month average by 0.35% (0.26).

Market Cap|Share Buybacks|EPS|All Metrics

VRTX Shares Outstanding Chart

VRTX Shares Outstanding
0.26-0.70% 1Y
Zoom

VRTX Average Shares Outstanding Chart

VRTX Current vs Average Shares Outstanding Chart

VRTX Shares Outstanding Metrics

SHARES OUTSTANDING

0.26

SHARES OUTSTANDING AVG TTM

0.26

SHARES OUTSTANDING AVG 3Y

0.26

SHARES OUTSTANDING AVG 5Y

0.26

SHARES OUTSTANDING AVG 10Y

0.25

SHARES OUTSTANDING AVG 15Y

0.24

SHARES OUTSTANDING AVG 20Y

0.21

CURRENT VS TTM AVG

-0.35%

CURRENT VS 3Y AVG

-0.41%

CURRENT VS 5Y AVG

-0.67%

CURRENT VS 10Y AVG

+0.86%

CURRENT VS 15Y AVG

+5.83%

CURRENT VS 20Y AVG

+19.03%

Share Structure

Shares Outstanding

255.70M

Float Shares

N/A

Stock Price

$436.96

Market Cap

$110.8B

Annual Shares Outstanding History

YearWeighted Average SharesYoY Change
2025255.70M-0.70%
2024257.50M-0.08%
2023257.70M+0.62%
2022256.10M-0.62%
2021257.70M-0.82%
2020259.84M+1.21%
2019256.73M+0.96%
2018254.29M+2.18%
2017248.86M+2.16%
2016243.59M+1.14%
2015240.84M+2.52%
2014234.92M+4.49%
2013224.83M+6.08%
2012211.95M+3.44%
2011204.89M+2.24%
2010200.40M+15.67%
2009173.26M+23.27%
2008140.56M+8.97%
2007128.99M+13.92%
2006113.22M+26.87%
200589.24M+13.58%
200478.57M+2.03%
200377.00M+1.66%
200275.75M+1.73%
200174.46M+10.02%
200067.68M+32.62%
199951.04M+0.87%
199850.60M+4.27%
199748.53M+29.81%
199637.38M-

Relationship: Market Cap = Shares Outstanding × Stock Price

Key concepts:

  • Float shares: Shares available for public trading
  • Dilution: When new shares are issued, existing shareholders own less
  • Buybacks: Reduce share count, increasing EPS and ownership stake
  • Stock splits: Increase share count but don't change market cap

Vertex Pharmaceuticals Incorporated Shares Outstanding Formula & Definition

Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Vertex Pharmaceuticals Incorporated Shares Outstanding FAQ

What is the shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The shares outstanding for VRTX stock is 0.26.
Is Vertex Pharmaceuticals Incorporated's shares outstanding high or low?
Vertex Pharmaceuticals Incorporated's shares outstanding of 0.26 is in line with its 5-year average of 0.26, near the low end of its 5-year range (0.26–0.26).
What is the TTM average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The TTM average shares outstanding for VRTX stock is 0.26.
What is the 3Y average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The 3Y average shares outstanding for VRTX stock is 0.26.
What is the 5Y average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The 5Y average shares outstanding for VRTX stock is 0.26.
What is the 10Y average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The 10Y average shares outstanding for VRTX stock is 0.25.
What is the 15Y average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The 15Y average shares outstanding for VRTX stock is 0.24.
What is the 20Y average shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)?
The 20Y average shares outstanding for VRTX stock is 0.21.

Vertex Pharmaceuticals Incorporated Shares Outstanding History

DATESHARES OUTSTANDING
2025-12-310.26
2024-12-310.26
2023-12-310.26
2022-12-310.26
2021-12-310.26
2020-12-310.26
2019-12-310.26
2018-12-310.25
2017-12-310.25
2016-12-310.24
2015-12-310.24
2014-12-310.23
2013-12-310.22
2012-12-310.21
2011-12-310.20
2010-12-310.20
2009-12-310.17
2008-12-310.14
2007-12-310.13
2006-12-310.11
2005-12-310.09
2004-12-310.08
2003-12-310.08
2002-12-310.08
2001-12-310.07
2000-12-310.07
1999-12-310.05
1998-12-310.05
1997-12-310.05
1996-12-310.04

Related Metrics

Market CapShare BuybacksEPSAll Metrics

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA
6,100 employees
www.vrtx.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
View full financials